A
Anupam Verma
Researcher at University of Utah
Publications - 27
Citations - 687
Anupam Verma is an academic researcher from University of Utah. The author has contributed to research in topics: Cancer & Asparaginase. The author has an hindex of 9, co-authored 27 publications receiving 513 citations. Previous affiliations of Anupam Verma include Huntsman Cancer Institute & Primary Children's Hospital.
Papers
More filters
Journal ArticleDOI
Targeting Axl and Mer kinases in cancer.
TL;DR: The role of Axl and Mer in normal cellular function and their role in oncogenesis are elucidated and the potential to inhibit these RTKs for the development of therapeutic targets in treatment of cancer is reviewed.
Journal ArticleDOI
Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.
Alexis Mollard,Steven L. Warner,Lee T. Call,Mark Wade,Jared Bearss,Anupam Verma,Sunil Sharma,Hariprasad Vankayalapati,David J. Bearss +8 more
TL;DR: A homology model of its catalytic domain was built to virtually screen and identify scaffolds displaying an affinity for AXL and resulted in the synthesis of a series of 2,4,5-trisubstitued pyrimidines which demonstrated potent inhibition of AXL in vitro and strongly inhibited the growth of several pancreatic cell lines.
Journal ArticleDOI
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
Weili Sun,Jemily Malvar,Richard Sposto,Anupam Verma,Jennifer J. Wilkes,Robyn M. Dennis,Kenneth Heym,Theodore W. Laetsch,Melissa Widener,Susan R. Rheingold,Javier Oesterheld,Nobuko Hijiya,Maria Luisa Sulis,Van Huynh,Andrew E. Place,Henrique Bittencourt,Raymond J. Hutchinson,Yoav Messinger,Bill H. Chang,Yousif Matloub,David S. Ziegler,Rebecca Gardner,Todd Cooper,Francesco Ceppi,Michelle L. Hermiston,Luciano Dalla-Pozza,Kirk R. Schultz,Paul S. Gaynon,Alan S. Wayne,James A. Whitlock +29 more
TL;DR: A retrospective study to determine the outcome of multiply R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013, which is the largest and most recent study to date that evaluates the outcome.
Journal ArticleDOI
Translating genomic discoveries to the clinic in pediatric oncology.
TL;DR: The translation of genomic discoveries to the clinic in pediatric oncology continues to move forward at a brisk pace and early adoption of genomics for tumor classification, risk stratification, and initial trials of targeted therapeutic agents has led to powerful results.
Journal ArticleDOI
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
Franco Locatelli,James A. Whitlock,Christina Peters,Christiane Chen-Santel,Victoria M. Chia,Robyn M. Dennis,Kenneth Heym,Aaron J. Katz,Michael A. Kelsh,Michael A. Kelsh,Richard Sposto,Huakang Tu,Catherine A. Tuglus,Anupam Verma,Luciana Vinti,Jennifer J. Wilkes,Jennifer J. Wilkes,Nathalya Zubarovskaja,Gerhard Zugmaier,Arend von Stackelberg,Weili Sun,Weili Sun +21 more
TL;DR: R/R pediatric ALL is rare; consequently, most studies are single-arm and limited by small population sizes, and one approach to estimate treatment efficacy is to identify appropriate control populations with similar characteristics.